Eurocine Vaccines has appointed Dr Anna-Karin Maltais as chief scientific officer and promoted business development manager Emma Berglund to chief business officer.
Dr Maltais, who also becomes head of R&D, takes over from Professor Jorma Hinkula, who has returned to his previous position as professor at the University of Linköping in Sweden.
In her new role, Dr Maltais will oversee Eurocine’s vaccines development programme, which includes Immunose – a nasal vaccine for influenza.
“Dr Maltais has extensive experience in vaccine development from both academia and industry,” said the company’s CEO Hans Arwidsson.
“Her expertise in vaccine delivery and adjuvants is extremely valuable to the company and with her industry background we can run our projects with an even stronger commercial focus.”
This includes several years at Cyto Pulse Sciences, where she served as manager EU operations and then VP, corporate development.
Berglund had been in her previous position since 2009, and has prior business development experience at both Biovitrum and Avaris.